Emerging pharmacological treatment options for MAFLD
Open Access
- 10 December 2022
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Endocrinology and Metabolism
- Vol. 13
Abstract
Metabolic dysfunction–associated fatty liver disease (MAFLD) prevalence and incidence is rising globally. It is associated with metabolic comorbidities, obesity, overweight, type 2 diabetes mellitus, and at least two metabolic risk factors, such as hypertension, hypertriglyceridemia, hypercholesterolemia, insulin resistance, and cardiovascular risk, increasing the risk of mortality. The excessive accumulation of fat comprises apoptosis, necrosis, inflammation and ballooning degeneration progressing to fibrosis, cirrhosis, and liver decompensations including hepatocellular carcinoma development. The limitation of approved drugs to prevent MAFLD progression is a paradigm. This review focuses on recent pathways and targets with evidence results in phase II/III clinical trials.Keywords
This publication has 106 references indexed in Scilit:
- Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2American Journal of Physiology-Gastrointestinal and Liver Physiology, 2012
- Fundamentals of FGF19 & FGF21 Action In Vitro and In VivoPLOS ONE, 2012
- Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXRNature Reviews Molecular Cell Biology, 2012
- Meta‐analysis: pioglitazone improves liver histology and fibrosis in patients with non‐alcoholic steatohepatitisAlimentary Pharmacology & Therapeutics, 2011
- Inhibition of Endothelin-1-Mediated Contraction of Hepatic Stellate Cells by FXR LigandPLOS ONE, 2010
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2010
- Fibroblast growth factor 21: from pharmacology to physiologyThe American Journal of Clinical Nutrition, 2010
- Olmesartan Prevents Cardiovascular Injury and Hepatic Steatosis in Obesity and Diabetes, Accompanied by Apoptosis Signal Regulating Kinase-1 InhibitionHypertension, 2008
- Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2Journal of Hepatology, 2006
- Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic SyndromeHepatology, 2003